| LXH254 | Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | Phase 2 | Active not recruiting | 134 | Feb 2, 2027 |
| LEE011 | Ribociclib (LEE011) Rollover Study for Continued Access | Phase 2 | Active not recruiting | 22 | Feb 1, 2027 |
| Alpelisib | Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer | Phase 2 | Active not recruiting | 69 | Jan 29, 2027 |
| Alpelisib | Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | Phase 3 | Active not recruiting | 210 | Jan 28, 2027 |
| JDQ443 | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 2 | Active not recruiting | 344 | Jan 25, 2027 |
| everolimus | Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | Phase 3 | Active not recruiting | 206 | Dec 30, 2026 |
| Fabhalta | Iptacopan in Patients With ANCA Associated Vasculitis | Phase 2 | Active not recruiting | 84 | Dec 30, 2026 |
| AAA617 | A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | Phase 2 | Active not recruiting | 49 | Dec 23, 2026 |
| AAA617 | Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function | Phase 2 | Active not recruiting | 23 | Dec 14, 2026 |
| Pelacarsen | An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | Phase 3 | Terminated | 41 | Oct 15, 2026 |
| JDQ443 | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 2 | Terminated | 74 | Sep 28, 2026 |
| YTB323 | An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus | Phase 2 | Completed | 21 | Sep 24, 2026 |
| JDQ443 | Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer | Phase 3 | Terminated | 95 | Sep 3, 2026 |
| Fabhalta | A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration | Phase 2 | Completed | 168 | Aug 19, 2026 |
| cyclosporine | A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) | Phase 3 | Terminated | 53 | Aug 6, 2026 |
| TQJ230 | Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD | Phase 3 | Completed | 8,323 | Jul 16, 2026 |
| Ilaris | A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer | Phase 2 | Completed | 41 | Jul 6, 2026 |
| KAE609 (Cipargamin) | Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1) | Phase 2 | Completed | 95 | Jun 17, 2026 |
| BION-1301 Single Dose | Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) | Phase 2 | Completed | 103 | Jun 10, 2026 |
| Ribociclib | First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer | Phase 2 | Completed | 74 | May 30, 2026 |
| Ribociclib | A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer | Phase 3 | Active not recruiting | 5,101 | May 29, 2026 |
| Rhapsido | A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines | Phase 3 | Active not recruiting | 362 | May 22, 2026 |
| CPK850 | A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa | Phase 2 | Completed | 12 | May 12, 2026 |
| Fabhalta | Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy | Phase 3 | Completed | 34 | Apr 11, 2026 |
| abelacimab | A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE | Phase 3 | Terminated | 417 | Apr 10, 2026 |
| Ribociclib + Letrozole OR Fulvestrant | Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype | Phase 3 | Terminated | 61 | Mar 26, 2026 |
| TQJ230 | Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD | Phase 3 | Completed | 422 | Mar 25, 2026 |
| Fabhalta | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | Phase 2 | Terminated | 81 | Mar 19, 2026 |
| Trametinib | PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer | Phase 2 | Terminated | 20 | Mar 3, 2026 |
| TIN816 70 mg lyophilisate powder | Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI) | Phase 2 | Completed | 316 | Feb 25, 2026 |
| Cosentyx | Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission | Phase 3 | Completed | 151 | Feb 24, 2026 |
| Ilaris | Evaluation of Canakinumab in High-Risk Former-Smokers | Phase 2 | Completed | 41 | Feb 4, 2026 |
| Metformin | A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma | Phase 2 | Completed · results | 62 | Feb 4, 2026 |
| NGI226 | A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy | Phase 2 | Completed | 45 | Feb 3, 2026 |
| Trametinib tablet | Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation | Phase 2 | Completed | 25 | Feb 2, 2026 |
| Sacubitril-valsartan | Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation | Phase 2 | Completed | 45 | Jan 31, 2026 |
| LDK378 | An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement | Phase 2 | Completed | 32 | Jan 29, 2026 |
| 20 mg baclofen vaginal suppository daily per vagina | Vaginal Baclofen Suppositories in Chronic Pelvic Pain | Phase 2 | Completed | 39 | Jan 1, 2026 |
| Trastuzumab | Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) | Phase 3 | Terminated | 27 | Dec 23, 2025 |
| Diovan | Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease | Phase 2 | Completed | 60 | Dec 20, 2025 |